Roles of the Apolipoprotein E Gene and Its Polymorphisms in the Etiopathophysiology of Type 2 Diabetes Mellitus and Its Atherosclerotic Complication in Senegalese Females
Lipid metabolism disorders would be among the components responsible for the risk of the onset of T2DM and its vascular complications. Apolipoprotein E plays an important role in lipid metabolism. We studied the involvement of the APOE gene in the onset of T2DM and its vascular complications. Clinical and biochemical parameters were assessed in each participant. APOE genotypes were identified by PCR-RFLP. Arterial stiffness was studied using a pOpmetre® which evaluates the pulse wave velocity (ft-PWV). Endothelial dysfunction was studied using an EndoPAT2000® which measures endothelium-dependent vasodilation (RHI). In control subjects, the ε3 allele was associated with an increase in fasting blood glucose (r = 2.36, p = 0.018), and a decrease in LDL cholesterol levels (r = −2.17, p = 0.03), and ε4 was associated with an increase in total cholesterol (r = 2.59, p = 0.01), LDL cholesterol (r = 2.84, p = 0.004), and No-HDL cholesterol (r = 2.74, p = 0.006). In type 2 diabetes subjects, the ε2 was associated with a decrease in diastolic blood pressure (r = −2.25, p = 0.02). The ε3 was associated with a decrease in ft-PWV (r = −2.26, p = 0.024) while the ε4 was associated with an increase in ft-PWV (r = 2.52, p = 0.012). Carrying the ε2ε3 genotype would have in 99% a limited risk of developing T2DM, and in event of T2DM, only 1 to 2% would have a significant risk of developing atherosclerosis, which would be severe in 17%. Of the ε2ε4 genotype, 93% had a limited or even possible risk of developing T2DM, the remaining 7% had a very high risk of developing T2DM. Diabetics carrying ε2ε4 had in 7% very high risk of developing atherosclerosis. The latter had a 20% very high risk of being very severe. Subjects carrying the ε3ε4 genotype had a 67% possible or even probable risk of developing T2DM and in the event of diabetes, there was in 34% very high risk of developing atherosclerosis which will not have even the time to evolve towards severity. For subjects carrying the ε3ε3, the risk of developing T2DM and athérosclerosis was higher than that of the ε2ε3, and ε2ε4 genotypes but lower than that
References
[1]
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A.A., Ogurtsova, K., Shaw, J.E., Bright, D. and Williams, R. (2019) Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Research and Clinical Practice, 157, Article ID: 107843. https://doi.org/10.1016/j.diabres.2019.107843
[2]
Cho, N.H., Shaw, J.E., Karuranga, S., Huang, Y., Da Rocha Fernandes, J.D., Ohlrogge, A.W. and Malanda, B. (2018) IDF Diabetes Atlas: Global Estimates of Diabetes Prevalence for 2017 and Projections for 2045. Diabetes Research and Clinical Practice, 138, 271-281. https://doi.org/10.1016/j.diabres.2018.02.023
[3]
Dajani, R., Li, J., Wei, Z., March, M.E., Xia, Q., Khader, Y., Hakooz, N., Fatahallah, R., El-Khateeb, M., Arafat, A., Saleh, T., Dajani, A.R., Al-Abbadi, Z., Abdul Qader, M., Shiyab, A.H., Bateiha, A., Ajlouni, K. and Hakonarson, H. (2017) Genome-Wide Association Study Identifies Novel Type II Diabetes Risk Loci in Jordan Subpopulations. PeerJ, 5, e3618. https://doi.org/10.7717/peerj.3618
[4]
De Ferranti, S.D., De Boer, I.H., Fonseca, V., Fox, C.S., Golden, S.H., Lavie, C.J., Magge, S.N., Marx, N., Mcguire, D.K., Orchard, T.J., Zinman, B. and Eckel, R.H. (2014) Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement from the American Heart Association and American Diabetes Association. Diabetes Care, 37, 2843-2863. https://doi.org/10.2337/dc14-1720
[5]
De Ferranti, S.D., De Boer, I.H., Fonseca, V., Fox, C.S., Golden, S.H., Lavie, C.J., Magge, S.N., Marx, N., Mcguire, D.K., Orchard, T.J., Zinman, B. and Eckel, R.H. (2014) Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement from the American Heart Association and American Diabetes Association. Circulation, 130, 1110-1130. https://doi.org/10.1161/CIR.0000000000000034
[6]
Hippisley-Cox, J. and Coupland, C. (2016) Diabetes Treatments and Risk of Amputation, Blindness, Severe Kidney Failure, Hyperglycaemia, and Hypoglycaemia: Open Cohort Study in Primary Care. The BMJ, 352, i1450. https://doi.org/10.1136/bmj.i1450
[7]
Franks, P.W., Pearson, E. and Florez, J.C. (2013) Gene-Environment and Gene-Treatment Interactions in Type 2 Diabetes: Progress, Pitfalls, and Prospects. Diabetes Care, 36, 1413-1421. https://doi.org/10.2337/dc12-2211
[8]
Shcherbak, N.S. (2001) Apolipoprotein E Gene Polymorphism Is Not a Strong Risk Factor for Diabetic Nephropathy and Retinopathy in Type I Diabetes: Case-Control Study. BMC Medical Genetics, 2, Article No. 8. https://doi.org/10.1186/1471-2350-2-8
[9]
Mahley, R.W. (2016) Apolipoprotein E: From Cardiovascular Disease to Neurodegenerative Disorders. Journal of Molecular Medicine, 94, 739-746. https://doi.org/10.1007/s00109-016-1427-y
[10]
Lin, Q.Y., Du, J.P., Zhang, M.Y., Yao, Y.G., Li, L., Cheng, N.S., Yan, L.N. and Xiao, L.J. (1999) Effect of Apolipoprotein E Gene Hha I Restricting Fragment Length Polymorphism on Serum Lipids in Cholecystolithiasis. World Journal of Gastroenterology, 5, 228-230. https://doi.org/10.3748/wjg.v5.i3.228
[11]
Rebeck, G.W., Ladu, M.J., Estus, S., Bu, G. and Weeber, E.J. (2006) The Generation and Function of Soluble apoE Receptors in the CNS. Molecular Neurodegeneration, 1, Article No. 15. https://doi.org/10.1186/1750-1326-1-15
[12]
Mahley, R.W. and Rall Jr., S.C. (2000) Apolipoprotein E: Far More than a Lipid Transport Protein. Annual Review of Genomics and Human Genetics, 1, 507-537. https://doi.org/10.1146/annurev.genom.1.1.507
[13]
Moreno, J.A., Perez-Jimenez, F., Marin, C., Gomez, P., Perez-Martinez, P., Moreno, R., Bellido, C., Fuentes, F. and Lopez-Miranda, J. (2004) The Effect of Dietary Fat on LDL Size Is Influenced by Apolipoprotein E Genotype in Healthy Subjects. The Journal of Nutrition, 134, 2517-2522. https://doi.org/10.1093/jn/134.10.2517
[14]
Davignon, J., Cohn, J.S., Mabile, L. and Bernier, L. (1999) Apolipoprotein E and Atherosclerosis: Insight from Animal and Human Studies. Clinica Chimica Acta, 286, 115-143. https://doi.org/10.1016/S0009-8981(99)00097-2
[15]
Kathiresan, S., Melander, O., Anevski, D., Guiducci, C., Burtt, N.P., Roos, C., Hirschhorn, J.N., Berglund, G., Hedblad, B., Groop, L., Altshuler, D.M., Newton-Cheh, C. and Orho-Melander, M. (2008) Polymorphisms Associated with Cholesterol and Risk of Cardiovascular Events. The New England Journal of Medicine, 358, 1240-1249. https://doi.org/10.1056/NEJMoa0706728
[16]
Higashi, Y., Noma, K., Yoshizumi, M. and Kihara, Y. (2009) Endothelial Function and Oxidative Stress in Cardiovascular Diseases. Circulation Journal, 73, 411-418. https://doi.org/10.1253/circj.CJ-08-1102
[17]
Vlachopoulos, C., Xaplanteris, P., Aboyans, V., Brodmann, M., Cifkova, R., Cosentino, F., De Carlo, M., Gallino, A., Landmesser, U., Laurent, S., Lekakis, J., Mikhailidis, D.P., Naka, K.K., Protogerou, A.D., Rizzoni, D., Schmidt-Trucksass, A., Van Bortel, L., Weber, T., Yamashina, A., Zimlichman, R., Boutouyrie, P., Cockcroft, J., O’rourke, M., Park, J.B., Schillaci, G., Sillesen, H. and Townsend, R.R. (2015) The Role of Vascular Biomarkers for Primary and Secondary Prevention. A Position Paper from the European Society of Cardiology Working Group on Peripheral Circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis, 241, 507-532. https://doi.org/10.1016/j.atherosclerosis.2015.05.007
[18]
Ohkuma, T., Ninomiya, T., Tomiyama, H., Kario, K., Hoshide, S., Kita, Y., Inoguchi, T., Maeda, Y., Kohara, K., Tabara, Y., Nakamura, M., Ohkubo, T., Watada, H., Munakata, M., Ohishi, M., Ito, N., Nakamura, M., Shoji, T., Vlachopoulos, C., Yamashina, A. and Collaborative Group for J-BAVEL. (2017) Brachial-Ankle Pulse Wave Velocity and the Risk Prediction of Cardiovascular Disease: An Individual Participant Data Meta-Analysis. Hypertension, 69, 1045-1052. https://doi.org/10.1161/HYPERTENSIONAHA.117.09097
[19]
Errera, F.I., Silva, M.E., Yeh, E., Maranduba, C.M., Folco, B., Takahashi, W., Pereira, A.C., Krieger, J.E. and Passos-Bueno, M.R. (2006) Effect of Polymorphisms of the MTHFR and APOE Genes on Susceptibility to Diabetes and Severity of Diabetic Retinopathy in Brazilian Patients. Brazilian Journal of Medical and Biological Research, 39, 883-888. https://doi.org/10.1590/S0100-879X2006000700005
[20]
Gavin III, J.R. (1998) New Classification and Diagnostic Criteria for Diabetes Mellitus. Clinical Cornerstone, 1, 1-12. https://doi.org/10.1016/S1098-3597(98)90014-X
[21]
Friedewald, W.T., Levy, R.I. and Fredrickson, D.S. (1972) Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, without Use of the Preparative Ultracentrifuge. Clinical Chemistry, 18, 499-502. https://doi.org/10.1093/clinchem/18.6.499
[22]
Mendes-Lana, A., Pena, G.G., Freitas, S.N., Lima, A.A., Nicolato, R.L., Nascimento-Neto, R.M., Machado-Coelho, G.L. and Freitas, R.N. (2007) Apolipoprotein E Polymorphism in Brazilian Dyslipidemic Individuals: Ouro Preto Study. Brazilian Journal of Medical and Biological Research, 40, 49-56. https://doi.org/10.1590/S0100-879X2007000100007
[23]
Corbo, R.M. and Scacchi, R. (1999) Apolipoprotein E (APOE) Allele Distribution in the World. Is APOE*4 a ‘Thrifty’ Allele? Annals of Human Genetics, 63, 301-310. https://doi.org/10.1046/j.1469-1809.1999.6340301.x
[24]
Tanyanyiwa, D.M., Marais, A.D., Byrnes, P. and Jones, S. (2016) The Influence of ApoE Genotype on the Lipid Profile and Lipoproteins during Normal Pregnancy in a Southern African Population. African Health Sciences, 16, 853-859. https://doi.org/10.4314/ahs.v16i3.28
[25]
Toure, M., Diouf, N.N., Thiam, S., Diop, J.P., Coly, M.S., Mbengue, A., Sar, F.B., Ba, A., Diallo, F.A. and Samb, A. (2022) Frequencies and Distribution of APOE Gene Polymorphisms and Its Association with Lipid Parameters in the Senegalese Population. Cureus, 14, e24063. https://doi.org/10.7759/cureus.24063
[26]
Huang, Z.H., Reardon, C.A. and Mazzone, T. (2006) Endogenous ApoE Expression Modulates Adipocyte Triglyceride Content and Turnover. Diabetes, 55, 3394-3402. https://doi.org/10.2337/db06-0354
[27]
Huang, Z.H., Luque, R.M., Kineman, R.D. and Mazzone, T. (2007) Nutritional Regulation of Adipose Tissue Apolipoprotein E Expression. American Journal of Physiology-Endocrinology and Metabolism, 293, E203-E209. https://doi.org/10.1152/ajpendo.00118.2007
[28]
Annuzzi, G., Holmquist, L. and Carlson, L.A. (1989) Concentrations of Apolipoproteins B, C-I, C-II, C-III, E and Lipids in Serum and Serum Lipoproteins of Normal Subjects during Alimentary Lipaemia. Scandinavian Journal of Clinical and Laboratory Investigation, 49, 73-81. https://doi.org/10.3109/00365518909089080
[29]
Chen, D.W., Shi, J.K., Li, Y., Yang, Y. and Ren, S.P. (2019) Association between ApoE Polymorphism and Type 2 Diabetes: A Meta-Analysis of 59 Studies. Biomedical and Environmental Sciences, 32, 823-838. https://doi.org/10.1101/530899
[30]
Wang, C., Yan, W., Wang, H., Zhu, J. and Chen, H. (2019) APOE Polymorphism Is Associated with Blood Lipid and Serum Uric Acid Metabolism in Hypertension or Coronary Heart Disease in a Chinese Population. Pharmacogenomics, 20, 1021-1031. https://doi.org/10.2217/pgs-2019-0048
[31]
Jemaa, R., Elasmi, M., Naouali, C., Feki, M., Kallel, A., Souissi, M., Sanhaji, H., Hadj Taieb, S., Souheil, O. and Kaabachi, N. (2006) Apolipoprotein E Polymorphism in the Tunisian Population: Frequency and Effect on Lipid Parameters. Clinical Biochemistry, 39, 816-820. https://doi.org/10.1016/j.clinbiochem.2006.04.018
[32]
Bennet, A.M., Di Angelantonio, E., Ye, Z., Wensley, F., Dahlin, A., Ahlbom, A., Keavney, B., Collins, R., Wiman, B., De Faire, U. and Danesh, J. (2007) Association of Apolipoprotein E Genotypes with Lipid Levels and Coronary Risk. JAMA, 298, 1300-1311. https://doi.org/10.1001/jama.298.11.1300
[33]
Davignon, J., Gregg, R.E. and Sing, C.F. (1988) Apolipoprotein E Polymorphism and Atherosclerosis. Arteriosclerosis, 8, 1-21. https://doi.org/10.1161/01.ATV.8.1.1
[34]
Weisgraber, K.H. (1990) Apolipoprotein E Distribution among Human Plasma Lipoproteins: Role of the Cysteine-Arginine Interchange at Residue 112. Journal of Lipid Research, 31, 1503-1511. https://doi.org/10.1016/S0022-2275(20)42621-5
[35]
Eichner, J.E., Dunn, S.T., Perveen, G., Thompson, D.M., Stewart, K.E. and Stroehla, B.C. (2002) Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review. American Journal of Epidemiology, 155, 487-495. https://doi.org/10.1093/aje/155.6.487
[36]
Utermann, G. (1985) Apolipoprotein E Mutants, Hyperlipidemia and Arteriosclerosis. In: Kritchevsky, D., Holmes, W.L. and Paoletti, R., Eds., Advances in Experimental Medicine and Biology, Springer, Boston, 173-188. https://doi.org/10.1007/978-1-4613-2459-1_14
[37]
Haddy, N., De Bacquer, D., Chemaly, M.M., Maurice, M., Ehnholm, C., Evans, A., Sans, S., Do Carmo Martins, M., De Backer, G., Siest, G. and Visvikis, S. (2002) The Importance of Plasma Apolipoprotein E Concentration in Addition to Its Common Polymorphism on Inter-Individual Variation in Lipid Levels: Results from Apo Europe. European Journal of Human Genetics, 10, 841-850. https://doi.org/10.1038/sj.ejhg.5200864
[38]
Yin, Y.W., Qiao, L., Sun, Q.Q., Hu, A.M., Liu, H.L., Wang, Q. and Hou, Z.Z. (2014) Influence of Apolipoprotein E Gene Polymorphism on Development of Type 2 Diabetes Mellitus in Chinese Han Population: A Meta-Analysis of 29 Studies. Metabolism: Clinical and Experimental, 63, 532-541. https://doi.org/10.1016/j.metabol.2013.12.008
[39]
Johnson, L.A., Torres, E.R., Impey, S., Stevens, J.F. and Raber, J. (2017) Apolipoprotein E4 and Insulin Resistance Interact to Impair Cognition and Alter the Epigenome and Metabolome. Scientific Reports, 7, Article No. 43701. https://doi.org/10.1038/srep43701
[40]
El-Lebedy, D., Raslan, H.M. and Mohammed, A.M. (2016) Erratum to: Apolipoprotein E Gene Polymorphism and Risk of Type 2 Diabetes and Cardiovascular Disease. Cardiovascular Diabetology, 15, Article No. 35. https://doi.org/10.1186/s12933-016-0354-0
[41]
Kim, J.S., Han, S.R., Chung, S.W., Kim, B.S., Lee, K.S., Kim, Y.I., Yang, D.W., Kim, K.S. and Kim, J.W. (2003) The Apolipoprotein E ε4 Haplotype Is an Important Predictor for Recurrence in Ischemic Cerebrovascular Disease. Journal of the Neurological Sciences, 206, 31-37. https://doi.org/10.1016/S0022-510X(02)00361-1
[42]
Amouyel, P., Vidal, O., Launay, J.M. and Laplanche, J.L. (1994) The Apolipoprotein E Alleles as Major Susceptibility Factors for Creutzfeldt-Jakob Disease. The Lancet, 344, 1315-1318. https://doi.org/10.1016/S0140-6736(94)90691-2
[43]
Hofmann, S.M., Perez-Tilve, D., Greer, T.M,. Coburn, B.A., Grant, E., Basford, J.E., Tschop, M.H. and Hui, D.Y. (2008) Defective Lipid Delivery Modulates Glucose Tolerance and Metabolic Response to Diet in Apolipoprotein E-Deficient Mice. Diabetes, 57, 5-12. https://doi.org/10.2337/db07-0403
[44]
Kockx, M., Jessup, W. and Kritharides, L. (2008) Regulation of Endogenous Apolipoprotein E Secretion by Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 1060-1067. https://doi.org/10.1161/ATVBAHA.108.164350
[45]
Mazzone, T., Gump, H., Diller, P. and Getz, G.S. (1987) Macrophage Free Cholesterol Content Regulates Apolipoprotein E Synthesis. The Journal of Biological Chemistry, 262, 11657-11662. https://doi.org/10.1016/S0021-9258(18)60860-9
[46]
Pendse, A.A., Arbones-Mainar, J.M., Johnson, L.A., Altenburg, M.K. and Maeda, N. (2009) Apolipoprotein E Knock-Out and Knock-In Mice: Atherosclerosis, Metabolic Syndrome, and Beyond. Journal of Lipid Research, 50, S178-S182. https://doi.org/10.1194/jlr.R800070-JLR200
[47]
Getz, G.S. and Reardon, C.A. (2009) Apoprotein E as a Lipid Transport and Signaling Protein in the Blood, Liver, and Artery Wall. Journal of Lipid Research, 50, S156-S161. https://doi.org/10.1194/jlr.R800058-JLR200
[48]
Wientgen, H., Thorngate, F.E., Omerhodzic, S., Rolnitzky, L., Fallon, J.T., Williams, D.L. and Fisher, E.A. (2004) Subphysiologic Apolipoprotein E (ApoE) Plasma Levels Inhibit Neointimal Formation after Arterial Injury in ApoE-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1460-1465. https://doi.org/10.1161/01.ATV.0000134297.61979.3c
[49]
Miyata, M. and Smith, J.D. (1996) Apolipoprotein E Allele-Specific Antioxidant Activity and Effects on Cytotoxicity by Oxidative Insults and β-Amyloid Peptides. Nature Genetics, 14, 55-61. https://doi.org/10.1038/ng0996-55
[50]
Corsetti, J.P., Bakker, S.J., Sparks, C.E. and Dullaart, R.P. (2012) Apolipoprotein A-II Influences Apolipoprotein E-Linked Cardiovascular Disease Risk in Women with High Levels of HDL Cholesterol and C-Reactive Protein. PLOS ONE, 7, e39110. https://doi.org/10.1371/journal.pone.0039110
